Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q5T160

UPID:
SYRM_HUMAN

ALTERNATIVE NAMES:
Arginyl-tRNA synthetase

ALTERNATIVE UPACC:
Q5T160; B2RDT7; Q96FU5; Q9H8K8

BACKGROUND:
Arginyl-tRNA synthetase, a key enzyme in mitochondrial protein synthesis, ensures the proper addition of arginine to tRNA molecules. This action is fundamental for the accurate translation of mRNA into proteins, highlighting its importance in cellular function.

THERAPEUTIC SIGNIFICANCE:
Linked to the development of Pontocerebellar hypoplasia 6, a condition characterized by significant neurological deficits, the study of Arginyl-tRNA synthetase's function and mutations offers a pathway to novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.